Rosen Law Firm announced on April 25 that it is investigating potential securities claims on behalf of shareholders of Disc Medicine, Inc. following allegations the company may have issued misleading business information.
The investigation comes after the U.S. Food and Drug Administration issued a Complete Response Letter to Disc Medicine regarding its bitopertin program on February 13, stating that the company’s new drug application could not be approved due to uncertainties requiring additional evidence. On the same day, Disc Medicine’s stock price fell by 22%.
“If you purchased Disc Medicine securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement,” Rosen Law Firm said in its statement. The firm is preparing a class action seeking recovery for investor losses.
Investors interested in joining the prospective class action are encouraged to visit Rosen Law Firm’s website or contact Phillip Kim, Esq., for more information about participating in the case. Rosen Law Firm said it represents investors globally and focuses its practice on securities class actions and shareholder derivative litigation. The firm also noted past achievements including securing what it described as “the largest ever securities class action settlement against a Chinese Company” and being ranked No. 1 by ISS Securities Class Action Services for number of settlements in 2017.
PR Newswire, which distributed this announcement, operates in more than 170 countries and supports over 40 languages according to the official website (https://www.prnewswire.com/). The service collaborates with over 500,000 media outlets and influencers globally according to the official website (https://www.prnewswire.com/), aiming to deliver global reach for press release distribution through its network as detailed on their official site (https://www.prnewswire.com/). PR Newswire also offers services such as AI-enhanced content tools, social sharing features, and support from expert editors with over a decade of experience providing guidance around-the-clock according to their official website (https://www.prnewswire.com/).
Rosen Law Firm advised investors considering participation in legal actions like this one: “Be wise in selecting counsel.” The firm emphasized its track record while noting that prior results do not guarantee similar outcomes.
